In last trading session, Turnstone Biologics Corp (NASDAQ:TSBX) saw 0.36 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $2.72 trading at $0.11 or 4.21% at ring of the bell on the day assigns it a market valuation of $62.91M. That closing price of TSBX’s stock is at a discount of -385.29% from its 52-week high price of $13.20 and is indicating a premium of 40.44% from its 52-week low price of $1.62. Taking a look at company’s average trading volume volume of 171.72K if we extend that period to 3-months.
Turnstone Biologics Corp (NASDAQ:TSBX) trade information
Upright in the green during last session for gaining 4.21%, in the last five days TSBX remained trading in the red while hitting it’s week-highest on Monday, 04/29/24 when the stock touched $2.72 price level, adding 9.33% to its value on the day. Turnstone Biologics Corp’s shares saw a change of 6.88% in year-to-date performance and have moved -1.45% in past 5-day. Turnstone Biologics Corp (NASDAQ:TSBX) showed a performance of -18.07% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Turnstone Biologics Corp (TSBX) estimates and forecasts
Statistics highlight that Turnstone Biologics Corp is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -23.38% of value to its shares in past 6 months, showing an annual growth rate of 30.13% while that of industry is 12.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
In 2024, company’s earnings growth rate is likely to be around 30.20% while estimates for its earnings growth in next 5 years are of 21.20%.
TSBX Dividends
Turnstone Biologics Corp is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
